These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28849261)

  • 41. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
    Zeppetella G; Messina J; Xie F; Slatkin NE
    Pain Pract; 2010; 10(4):287-93. PubMed ID: 20230447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
    Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
    Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
    Weinstein SM; Messina J; Xie F
    Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
    Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
    Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
    Zucco F; Bonezzi C; Fornasari D
    Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
    Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
    Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.
    Vissers D; Stam W; Nolte T; Lenre M; Jansen J
    Curr Med Res Opin; 2010 May; 26(5):1037-45. PubMed ID: 20199140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
    Webster LR; Messina J; Xie F; Nalamachu S
    J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
    Darwish M; Xie F
    Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
    Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
    J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breakthrough cancer pain in 2020.
    Løhre ET; Thronæs M; Klepstad P
    Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
    Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
    Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.